A股異動 | 科華生物跌6% 控股子公司不配合審計工作 公司表示強烈憤慨和譴責
格隆匯12月28日丨科華生物(002022.SZ)現跌6.67%,報13.86元,總市值71億元。科華生物12月27日發佈公吿,公司依法持有天隆公司62%的股權,是天隆公司的控股股東。天隆公司以向公司開放財務資料存在商業祕密泄露風險等為由,明確表示目前無法配合科華生物預審會計報表以及後續的審計工作。公司認為,天隆公司在《審計工作回覆函》中提出的所謂“理由”完全缺乏事實和法律依據!對於李明等天隆公司部分董事、高級管理人員無視證券市場規則和公司規範運作要求,漠視上市公司及其中小股東利益的行為,公司表示最強烈憤慨和譴責!

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.